SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

Greece approves $750M rocket deal with Elbit amid negotiations for $3.5B Israeli air-defense systems

Intel VP: “We’re just not going to accept subpar products”

Intel’s decision to keep NEX signals stability for Israel’s 350 networking staff

Buzz

Most popular

Daily

Weekly

1

“Other countries have air-defense systems, but Israel’s are better”: Arrow 3 lands in Germany as Israel pursues new mega deals

2

Nice puts Actimize up for sale at a $1.5-2 billion price tag

3

Zafran raises $60 million and doubles valuation as it chooses independence over takeover offers

4

Israeli drone startup Heven hits $1 billion valuation in $100 million round led by IonQ

5

Cybereason founders' 7AI raises record $130 million Series A in breakneck rise

Weight Loss

4 stories about Weight Loss

גלולת הרזיה של אפיטומי

Epitomee surges 200% in two days on FDA approval for weight loss pill

16.09.24|Adiel Eithan Mustaki

Investors are hopeful, but the company must now face an uphill battle in a crowded market.

גלולת הרזיה של אפיטומי

Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement

04.12.23|Adiel Eithan Mustaki

The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level

גלולה של חברת אפיטומי epitomee

Weight loss pill success sparks stock surge at Epitomee Medical

04.09.23|Adiel Eithan Mustaki

The company, which has not yet published the full results of its study, plans to seek FDA approval via the 510(k) pathway

מוסף תרופה תרופות בית מרקחת

Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns

16.02.20|Lilach Baumer

On Thursday, the manufacturer of Belviq weight loss drug, Eisai, announced it was withdrawing the drug from the U.S. market after a five-year trial found it increased risk of cancer by 0.6%